CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of $823.20 million. The enterprise value is $536.39 million.
| Market Cap | 823.20M |
| Enterprise Value | 536.39M |
Important Dates
The next estimated earnings date is Thursday, August 15, 2024, before market open.
| Earnings Date | Aug 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CureVac has 224.31 million shares outstanding. The number of shares has increased by 17.68% in one year.
| Shares Outstanding | 224.31M |
| Shares Change (YoY) | +17.68% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 45.27% |
| Owned by Institutions (%) | 21.68% |
| Float | 122.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 9.17 |
| PS Ratio | 12.84 |
| Forward PS | n/a |
| PB Ratio | 1.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.25, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.25 |
| Quick Ratio | 1.90 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -143.76 |
Financial Efficiency
Return on equity (ROE) is -49.40% and return on invested capital (ROIC) is -58.90%.
| Return on Equity (ROE) | -49.40% |
| Return on Assets (ROA) | -33.90% |
| Return on Capital (ROIC) | -58.90% |
| Revenue Per Employee | $54,721 |
| Profits Per Employee | -$253,470 |
| Employee Count | 1,172 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 5.72 |
Taxes
In the past 12 months, CureVac has paid $940,032 in taxes.
| Income Tax | 940,032 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.26% in the last 52 weeks. The beta is 2.64, so CureVac's price volatility has been higher than the market average.
| Beta (5Y) | 2.64 |
| 52-Week Price Change | -63.26% |
| 50-Day Moving Average | 3.58 |
| 200-Day Moving Average | 4.01 |
| Relative Strength Index (RSI) | 55.76 |
| Average Volume (20 Days) | 1,312,649 |
Short Selling Information
The latest short interest is 6.10 million, so 2.72% of the outstanding shares have been sold short.
| Short Interest | 6.10M |
| Short Previous Month | 5.89M |
| Short % of Shares Out | 2.72% |
| Short % of Float | 4.98% |
| Short Ratio (days to cover) | 4.63 |
Income Statement
In the last 12 months, CureVac had revenue of $64.13 million and -$297.07 million in losses. Loss per share was -$1.33.
| Revenue | 64.13M |
| Gross Profit | -94.13M |
| Operating Income | -312.80M |
| Pretax Income | -296.76M |
| Net Income | -297.07M |
| EBITDA | -270.31M |
| EBIT | -294.71M |
| Loss Per Share | -$1.33 |
Balance Sheet
The company has $331.09 million in cash and $44.27 million in debt, giving a net cash position of $286.82 million or $1.28 per share.
| Cash & Cash Equivalents | 331.09M |
| Total Debt | 44.27M |
| Net Cash | 286.82M |
| Net Cash Per Share | $1.28 |
| Equity (Book Value) | 486.80M |
| Book Value Per Share | 2.17 |
| Working Capital | 228.69M |
Cash Flow
In the last 12 months, operating cash flow was -$288.50 million and capital expenditures -$48.33 million, giving a free cash flow of -$336.82 million.
| Operating Cash Flow | -288.50M |
| Capital Expenditures | -48.33M |
| Free Cash Flow | -336.82M |
| FCF Per Share | -$1.50 |
Margins
Gross margin is -146.78%, with operating and profit margins of -487.74% and -463.21%.
| Gross Margin | -146.78% |
| Operating Margin | -487.74% |
| Pretax Margin | -462.72% |
| Profit Margin | -463.21% |
| EBITDA Margin | -421.48% |
| EBIT Margin | -459.53% |
| FCF Margin | -525.20% |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.68% |
| Shareholder Yield | -17.68% |
| Earnings Yield | -36.09% |
| FCF Yield | -40.92% |
Analyst Forecast
The average price target for CureVac is $10.00, which is 172.48% higher than the current price. The consensus rating is "Hold".
| Price Target | $10.00 |
| Price Target Difference | 172.48% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 18.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of -2.3 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.3 |
| Piotroski F-Score | 4 |